Intentar ORO - Gratis
WHO on the centre stage
BioSpectrum Asia
|BioSpectrum Asia September 2020
The COVID-19 pandemic, with Wuhan in China as its epicenter has wreaked havoc worldwide on a monumental scale. Nations of the world were caught unawares and so was the World Health Organization (WHO). It would seem that this globally active organization has not been able to lead the world in response to the pandemic. While some countries have been trying to fight and contain the spread on their own terms, many countries rely on the WHO for its experience in handling pandemics in the past. The United States of America, and particularly President Donald Trump has been a vocal critic of the WHO. We will take a look at how the global organization has handled previous epidemics and whether its criticism is warranted.
This is, perhaps, the first time since the WHO was established in 1948, that it is tasked with handling an epidemic of such magnitude. The pandemic, first detected in December 2019, still rages on, killing 788,000 and affecting 22.4 million globally, according to the data from Johns Hopkins University Center for Systems Science and Engineering (as on August 20, 2020).
With an unknown virus, many early assumptions and strategies had failed. There was little success in containing the spread of the virus. The WHO has been criticised for its delayed declaration of a worldwide emergency, ambiguous guidelines about the use of masks and a delay in prohibiting international flights. It also delayed in suggesting that there may be airborne spread of infection in addition to the droplet spread of infection.
While the US government has stopped funding to the organization, most experts in the scientific and medical field are positive about how the organization has handled the crisis.
Votaries of WHO
Esta historia es de la edición BioSpectrum Asia September 2020 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits
US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation
US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio
Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema
A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing
Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO
Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
IIT-D and AIIMS develop swallowable microdevice for microbiome study
Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Ambitious research to develop multivalent vaccines against multiple deadly filoviruses
Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.
1 min
BioSpectrum Asia Feb 2026
Translate
Change font size
